33 results about "Oct-4" patented technology

The invention provides a quiescent stem cell having the capacity to differentiate into ectoderm, mesoderm and endoderm, and which does not express cell surface markers including MHC class I, MHC class II, CD44, CD45, CD13, CD34, CD49c, CD73, CD105 and CD90. The invention further provides a proliferative stem cell, which expresses genes including Oct-4, Nanog, Sox2, GDF3, P16INK4, BMI, Notch, HDAC4, TERT, Rex-1 and TWIST but does not express cell surface markers including MHC class I, MHC class II, CD44, CD45, CD13, CD34, CD49c, CD73, CD105 and CD90. The cells of the invention can be isolated from adult mammals, have embryonic cell characteristics, and can form embryoid bodies. Methods for obtaining the stem cells, as well as methods of treating diseases and differentiated the stem cells, are also provided.

The invention relates to a method for extracting sub-totipotent stem cells from a chorion of a fetal surface of a placenta. The method comprises the steps of removing an amnion and stagnated blood from the placenta, and then repetitively washing the surface of the placenta to perform sterilization; shearing the chorion of the fetal surface in a glass utensil, removing placenta lobule tissues remained on the surface as much as possible, and shearing the chorion into small blocks; washing small tissue blocks by using a screen and a great amount of normal saline, and removing residual blood cells; performing tissue digestion: performing oscillatory digestion in a constant temperature shaker by using mixed enzymes; adding a proper amount of FBS for termination after digestion, performing filtration through a filter screen, and adding a great amount of normal saline to wash filter residues to obtain cells as many as possible; performing centrifugation, abandoning supernatant, adding saline water for washing and performing centrifugation to obtain mononuclear cells; performing magnetic bead sorting (OCT-4 positive, Nanog positive and STRO-1 negative) to obtain target cells. The invention further relates to the sub-totipotent stem cells obtained by adopting the method and pharmaceutical use thereof. The sub-totipotent stem cells have excellent characteristics.

The invention relates to the technical field of medical biology engineering, and provides an anti-human Oct 4 (octamer-binding protein 4) monoclonal antibody, recombinant protein for preparing the monoclonal antibody, a hybridoma cell strain secreting the monoclonal antibody as well as applications of the monoclonal antibody in western blot, expression of Oct 4 in immunohistochemical detection samples and preparation of prognosis evaluation preparations for liver cancer.

The present invention relates to multipotent adult stem cells expressing Oct4, derived from umbilical cord blood (UCB) and also these cell are expressing CD29, CD31, CD44, simultaneously, a method for preparing the same, and more specifically to multipotent adult stem cells which are obtained by culturing umbilical cord blood-derived monocytes in a medium containing bFGF (basic fibroblast growth factor) and human serum or plasma. In addition, multipotent adult stem cells expressing Oct-4 from UCB are morphologically spindle or round shaped cells Although the stem cells according to the present invention are adult stem cells, they are multipotent and capable of differentiating into ectodermal-, messodermal-, endodermal-originated tissue or cells including osteogenic cells or nerve cells etc, thus they can be effectively used in the treatment of intractable diseases and incurable diseases.

The invention provides a method for inhibiting PUMA function and improving iPS (induced Pluripotent Stem) cell construction effect. The method comprises the following steps of: (1) preparing fibroblast MEF (Mouse Embryonic Fibroblast) of a PUMA-/- (PUMA gene knocked out) mice or PUMA-/+ mice, and performing passage and frozen storage; (2) converting plasmid PMX-Oct 4, PMX-Sox2, PMX-c-Myc and PMX-KLF4 through DH5 alpha escherichia coli strain, and respectively highly and slightly extracting plasma; (3) packing retrovirus, tittering and performing frozen storage; (4) knocking out reprogramming of embryo fibroblasts MEF of the mice or PUMA-/+ mice through PUMA gene; and (5) knocking down the programming of human fibroblast of the PUMPA function. The method has the beneficial effects that the PUMA function is inhibited and the iPS cell construction effect is improved during programming somatic cell; the stability of iPS cell genome can be protected at the same time.

The invention relates to a pair of human embryonic stem cell lines with the same HLA property. The paired human embryonic stem cell lines have the same HLA property, normal karyograms and higher affinities for expressing specific surface antigens; the paired human embryonic stem cell lines are strongly positive through AKP detection, and simultaneously, can express Oct-4 transcription factors and display undifferentiated properties; and the average population doubling time is about 32 hours. More choices for solving HLA mating difficulty are provided by researching the properties of the pair of human embryonic stem cell lines from the same male parent and the same female parent in biology, genetics and epigenetics, and meanwhile, the two embryonic stem cell strains provide good models for clinical basic research.

The present invention relates to a novel method for preparing induced pluripotent stem cells (iPSCs) by introducing four genes, Oct-4, Sox2, Klf4, and Glial, into somatic cells. The present invention also relates to the iPSCs produced by the aforementioned method. Also provided is a process of drug selection for a heritable genetic disease by use of the iPSCs produced by the aforementioned method. In particular, wherein the inherited disease is Fabry disease. The present invention also relates to a method for treating Fabry-associated myocardiopathy in a subject in need thereof, and a method for determining prognosis in a subject with Fabry-associated myocardiopathy.

The present invention relates to a cancer initiating cell comprising an isolated coxsackievirus and adenovirus receptor positive mouse pulmonary stem/progenitor cell that overexpresses Oct-4.